Pharmacist intervention in treatment of patients with genotype 1 chronic hepatitis C.
Marino
Eduardo L
EL
Department of Pharmacy and Pharmaceutical Technology, University of Barcelona, Faculty of Pharmacy. Av. Joan XXIII s/n, Barcelona, Spain 08028. emarino@ub.edu
Alvarez-Rubio
Luis
L
Miro
Silvia
S
Modamio
Pilar
P
Banos
Fernando
F
Lastra
Cecilia F
CF
Alberdi-Leniz
Aintzane
A
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010595:Pharmacists / Q000458:organization & administration*; D010607:Pharmacy Service, Hospital / Q000458:organization & administration*; D011092:Polyethylene Glycols; D024382:Professional Role; D011446:Prospective Studies; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D013030:Spain; D016896:Treatment Outcome; D016903:Drug Monitoring
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b